BioSpace News Archive

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced $30 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, to accelerate commercialization of its leading smoking cessation solution, Clickotine™, and to advance its pipeline of clinically-validated digital therapeutics. “This financing will hel

Octapharma USA will present its most recent rare bleeding disorders research initiatives during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 – 8.

Vystar Corporation (OTCQB: VYST) and the Indian Rubber Manufactu rers Research Association (IRMRA) have signed a Memorandum of Understanding (MoU) for a wide range of collaborative activities, including but not limited to research, innovation, testing and technology transfer in midstream and downstream sectors of the rubber industry. IRMRA is an internationally renowned Research and Development Centre

Prescient Medicine Holdings, Inc., a privately held company focused on developing insights-based health tools, today announced its rebrand to SOLVD Health. The new name and brand reflect the comp

Calviri, a biotechnology company developing unique products against cancer, is pleased to announce that it was awarded one of three Platinum awards in the Pepperdine Graziadio Business School’s third annual Most Fundable Companies® List.

The first manufacturing service of its kind delivers tested sterile, non-GMP media designed for feasibility testing before scale-up, to support development of cell and gene therapies

CCT Research, a leader in community-based, embedded clinical research, today announced the expansion of its clinical trial operations to the Salt Lake City metropolitan area.

Clinical-stage cannabinoid development company Incannex Healthcare Limited (ASX: IHL) has announced its plans to request an expedited pre-IND meeting for its anti-inflammatory IHL-675 and to pursue an FDA Emergency Use Authorization (EUA) for the treatment of patients suffering from COVID-19.

Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that Dr. Darrin M. Beaupre will join the company as its Chief Medical Officer, Oncology.

Combination of free user-friendly web tool, to obtain custom probe sequences, and enzyme-based technology allows for efficient depletion of abundant RNAs for virtually any organism and sample type.